As reported on Pharmaceutical Technology, Alentis Therapeutics has expanded its efforts in claudin-1-targeted cancer therapeutics through a newly announced partnership with PinotBio, aimed at generating antibody-drug conjugates (ADCs) for multiple…
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent Bruton tyrosine kinase (BTK) inhibitor,…
As reported on World Pharma News, a collaborative research team from the Medical University of Vienna, HUN-REN Research Centre for Natural Sciences, and Eötvös Loránd University has unveiled a promising…
Merck & Co. announced positive results from two Phase 3 studies of its kidney cancer drug Welireg, signaling potential expansion into earlier stages of disease. As reported on BioPharmaDive, in…
A collaborative team from Arc Institute, Gladstone Institutes, and UCSF has unveiled a groundbreaking epigenetic editing platform that could revolutionize next-generation cell therapies. Published in Nature Biotechnology on October 21,…
Astellas Pharma Inc. has announced that its Phase 2 GLEAM trial evaluating zolbetuximab in combination with gemcitabine plus nab-paclitaxel for metastatic pancreatic adenocarcinoma did not meet its primary endpoint of…
This past September, the urothelial cancer field witnessed several groundbreaking developments, offering new hope for patients and fresh strategies for clinicians. As reported by OncLive.com, from regulatory milestones to innovative…
Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…
A groundbreaking study from the Molecular Oncology Research Center at Hospital de Amor in Barretos, Brazil, is paving the way for more personalized and less toxic treatments for children with…
In a breakthrough study, scientists have uncovered a surprising ally in the fight against cancer: the bacteria living within tumors. According to World Pharma News, an international team led by…
Dewpoint Therapeutics, a U.S.-based biotechnology innovator, has announced the successful closure of its Series D financing round. As reported by thepharmaletter, Dewpoint Therapeutics is renowned for its pioneering work in…
Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…
Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…
Recent research outlined by Medical Xpress offers a deeper understanding of why CDK4/6 inhibitors, a class of drugs widely used to treat certain cancers, sometimes fail to deliver lasting benefits.…
A significant milestone has been achieved in the fight against blood cancers, as the first patient has been dosed in a pivotal Phase 3 clinical trial evaluating a promising new…
In a remarkable stride toward personalized cancer treatment, scientists have developed a groundbreaking test designed to predict whether individual patients will respond to chemotherapy or develop resistance. According to Bioengineering.com,…
Myrovlytis Trust, a UK-based charity and Patient Worthy partner, has developed a new resource for those facing osteosarcoma. This devastating cancer often occurs in childhood, teen, and young adult years.…
According to a recent article, $100 million has been given to four research teams by the Cancer Grand Challenges program for cancer research. Cancer Grand Challenges Program The Cancer…
Over the last few years, many researchers have been utilizing organoids as a pathway to learn more about diseases and spur drug development. Organoids may be helpful, moving forward, in…
Currently, there are a number of potential treatment options for patients with multiple myeloma: immunomodulators, chemotherapy, HDAC inhibitors, steroids, and proteasome inhibitors. But according to Medical XPress, Peter Mac scientists…
Each year, around 14,000 U.S. deaths are attributed to ovarian cancer. Yet researchers have historically struggled to find an exact cause of the cancer, or to understand exactly how…
Those diagnosed with paraganglioma-pheochromocytoma, squamous cell carcinoma of the skin (cSCC), adrenocortical carcinoma (ACC), and carcinoma of unknown primary (CUP) may soon have an additional option for treatment. According to…
According to a January article from The Shields Gazette, nearly 21% of cancer patients from South Tyneside in the UK were first diagnosed without any prior knowledge during emergency admissions…
According to a press release from British biopharmaceutical manufacturer Autolus Therapeutics, the American Food and Drug Administration (FDA) has granted the Company's experimental acute lymphoblastic leukemia (ALL) cell-based immunotherapy treatment…
According to a publication from Live Science, researchers from around the world are working on a way to identify cancer in the body more efficiently and reliably. One way scientists…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
